Experts Ponder Ways to Fill Pharma Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Experts Ponder Ways to Fill Pharma Pipeline
FDA, NIH and industry seek new strategies to spur drug development and promote access to therapies.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 28-34


Jill Wechsler
Drug-development pipelines have shrunk; fewer new products are being approved for market; and the prospect of significant declines in revenues due to the looming "patent cliff" is prompting pharmaceutical companies to scale back research and development (R&D). Pfizer rocked the industry in February by announcing a major cutback in R&D spending, including plans to shutter its long-time research facility in Sandwich, United Kingdom, and to reduce its Groton, Connecticut, research facility. As part of a move to cut its $9-billion R&D budget to some $6-7 billion by 2012, Pfizer is moving antibacterial research from Groton to Shanghai, China, and will use its Cambridge, Massachusetts, research operation to form more links with small biotechnology firms in the area.

The crisis in the pharmaceutical industry is generating a serious search for new business models. Manufacturers are looking to partner more with small biotechnology firms and academic research institutes, to shift research and production operations overseas, and to streamline operations and reduce waste wherever possible. The National Institutes of Health (NIH) proposes to ramp up support for translational medicine that will shepherd basic research through the R&D "valley of death" to yield new therapies. Patient advocacy groups are consulting with and providing funding for public and private therapy development programs. America's position as the world leader in biomedical R&D is "under siege today," and facing its biggest threat in 65 years, commented former Congressman John Porter, at a forum in March 2011, sponsored by ResearchAmerica. "Is America going to put progress on hold?" he asked in calling for decision-makers to consider the importance of science and innovation in making spending decisions. These trends are shaping many aspects of biopharmaceutical development, production, and marketing.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here